Biotech, in brief

Researchers grew muscle cells from a mouse's own thigh and injected them under the skin of its back. [1]

The cells organised into real muscle tissue, grew their own blood supply, and contracted continuously for months. [1][2]

The graft is attached to no bone and no tendon. It moves nothing and does no work. [1][2]

Older mice with a graft carried more lean mass after eight weeks and had denser bone after fifteen. [1]

They also ran farther, gripped harder, and explored more of a maze than mice without one. [1]

Mice fattened on a high-fat diet had less body fat, lower blood sugar and a smaller cholesterol rise. [1]

Signs of body-wide inflammation fell too: fewer white blood cells, lower fats in the blood, less liver damage. [1]

The benefits landed in bone, fat, liver and brain. The graft touches none of them. [1]

So the good arrives as chemistry. A working muscle releases signal proteins into the blood, and those travel. [1][2]

The team also gave grafts the genes for two hormones, so the tissue made those drugs continuously. [2]

It is mice, and the authors call it a proof of concept. [1]

James White of Duke University says a person would probably need several grafts, meaning several operations. [1]

Why it matters. Watch whether the graft works in an animal larger than a mouse, and how many a person would need - that number decides everything. [1]

The FDA approved updated Covid vaccines on Thursday, for everyone 65 and over and for younger people with a qualifying condition. [3]

Why it matters. Pfizer said it would ship immediately, but the eligibility rules and a legal dispute could still block some people.

Two unvaccinated Lancaster County residents died of measles, the first US deaths this year. The CDC counted 2,777 cases in 2026. [4][5][6]

Why it matters. That is the worst US year since 1991, and five deaths in two years, more than the whole of the previous three decades. [4]

The FDA approved Lisraya, a once-daily tablet, for dermatomyositis in adults - a rare disease in which the immune system attacks muscle and skin. [7]

Why it matters. It is the first oral option, from a 241-patient trial, and carries a boxed warning for infections, cancers, clots and death. [7]

The AP and the Guardian obtained a 2019 letter in which Robert F. Kennedy Jr. asked Samoa's prime minister to let him study its measles vaccines. [8]

Why it matters. He told senators weighing his confirmation the trip had nothing to do with vaccines. The letter uses the word eight times. [8]

Toronto researchers inhaled engineered transfer RNAs into mice and patient-derived tissue. Cells read past a faulty stop signal and made working CFTR protein. [9]

Why it matters. Stop-signal mutations of this kind cause about 11% of human genetic disorders. This was cells, mice and lab-grown tissue, not people. [9]

AstraZeneca and Amgen said Tezspire met every goal of a late-stage trial in a swallowing disorder called eosinophilic esophagitis. No figures were released. [10]

Why it matters. More than 470,000 Americans have the condition, and the drug already sells over $1bn a year. [10]

Six people with severe rheumatoid arthritis got one dose of their own immune cells, re-engineered to strip out the B cells making the harmful antibodies. [11]

Why it matters. All six had only a mild inflammatory reaction, none had lasting harm, and the trial moves to its second stage. [11]

Among US adults over 60, the newer shingles vaccine was linked to a 9% lower burden of heart disease, heart failure and stroke over seven years. [12]

Why it matters. The authors used a swift national switch between two shingles vaccines as a natural comparison, then called for real trials. [12]

In the STAR-TREC trial, four in five patients given chemotherapy and radiotherapy avoided major surgery for up to a year, against three in five on radiotherapy alone. [13]

Why it matters. Standard treatment often means losing the rectum and living with a permanent stoma bag. Thirty-month results are still being analysed. [13]

Pennsylvania governor Josh Shapiro said he was very blunt with Kennedy about the administration's rhetoric on vaccines. Kennedy accused him of gaslighting. [14]

Why it matters. International officials meet in November to decide whether the US has lost the measles-free status it has held since 2000. [4]

In Merck and Moderna's personalised cancer vaccine, software reads thousands of tumour mutations and picks 34 targets to encode. The rules are not public. [15]

Why it matters. Moderna is raising $2bn a week after the trial succeeded, while some investors doubt the personalising step is needed at all. [15]

The FDA approved zanidatamab with tislelizumab as a first treatment for HER2-positive stomach and oesophageal cancer, plus two tests that find the right patients. [16]

Why it matters. It rests on HERIZON-GEA-01, a three-arm global trial measuring both time without growth and overall survival. [16]

About one in five people carry high levels of Lp(a), a blood particle set largely by genetics that raises heart risk. Novartis leads several late-stage trials. [39]

Why it matters. Diet and current drugs barely shift it, so there is nothing to offer the people who have it. [39]

Cardiologists meet in Munich on Friday to hear why AstraZeneca and Ionis's eplontersen failed to cut cardiovascular deaths in a disease caused by a misfolded protein. [40]

Why it matters. Alnylam sells two drugs for the same disease, so a rival's failure clouds how well the whole approach works. [40]

Bloomberg reported the White House will announce another round of drug-pricing deals with mid-sized biotechs. Reuters said it could not verify the report. [17]

Why it matters. Seventeen companies have already signed, agreeing to charge state Medicaid programmes what they charge abroad. [17]

The drug distributor McKesson agreed to buy Precision Medicine Group, which runs clinical trials and product launches, for about $2.25bn. [18]

Why it matters. It joins McKesson's cancer arm, moving the company that ships the drugs closer to the trials that create them. [18]

MassBio reported seed funding for Massachusetts startups fell 39% in the first half of 2026, to $4.65m. The state lost 3,605 biopharma jobs. [19]

Why it matters. Later-stage money is plentiful. The shortfall sits at the front end, where new companies are made. [20]

Licensing deals for drugs discovered in China brought $79bn last year, against about $1bn in 2019. China now runs more early-stage trials than anywhere else. [20]

Why it matters. A proposed US bill to curb those ties could push the deals through Europe instead, executives told STAT. [15]

Sentivera emerged with $83m and a deal worth up to $1.46bn, paying Haisco Pharmaceutical $40m upfront for an inflammation drug cleared to start trials in China. [21]

Why it matters. The same investors sold Metsera to Pfizer after a bidding war, then incorporated Sentivera twelve days later. [21]

The FDA delayed its verdict on Capricor's Duchenne cell therapy by three months, after the company filed follow-up data narrowing it to upper-limb function. [22]

Why it matters. Late data counts as a major amendment, which restarts part of the review clock. [22]

Cellares, which automates the making of cell therapies, is laying off 100 people by 20 October, mostly software engineers and quality staff. [23]

Why it matters. It is the second cell-therapy manufacturer to cut staff this year, while the therapies themselves keep winning approvals. [23]

Aged mice make too many of one kind of white blood cell. Blocking a single signal with maraviroc, an approved HIV drug, reversed that. [24]

Why it matters. That cell ratio predicts death in older people, so a licensed drug now has an ageing question attached to it. [24]

Yale researchers found moderate calorie cutting lowers an immune protein called C3. Blocking C3 directly reduced age-related inflammation in mice, with no dieting. [25]

Why it matters. Severe restriction makes mice prone to infection and stunts growth, which is why a substitute is being hunted. [25]

A nanoparticle cage carrying antibodies turned astrocytes, the brain's support cells, into new neurons in mice with an Alzheimer's-like condition. The mice thought better. [26]

Why it matters. The team hopes to test it in people within a few years. Nothing here has been tried in a human brain. [26]

Researchers used model guidance on thin data to evolve a compact gene editor, FanzMAX, hitting 97% editing at its best site and beating two rivals 2.6-fold. [27]

Why it matters. Small editors fit into delivery vehicles the big ones do not. This one edited a cholesterol gene in humanised mice. [27]

A new carrier particle delivered RNA, including CRISPR machinery, into the cornea's inner cell layer in mice, a human donor eye and a monkey. [28]

Why it matters. That layer does not regenerate, and its failure causes several blinding conditions. The particle can also be given more than once. [28]

Mice lacking cGAS, a sensor that spots stray DNA, aged faster and died sooner. Old jumping genes woke up and set off inflammation. [29]

Why it matters. Groups have been trying to block cGAS to slow ageing. This says the same protein also holds the genome quiet. [29]

Researchers assembled near-complete genomes for eight Myotis bat species, whose lifespans differ widely, and found selection tied to longevity, cancer resistance and virus tolerance. [30]

Why it matters. These bats handle DNA viruses and RNA viruses by different genetic routes from every other mammal studied. [30]

Children whose first 1,000 days fell under postwar British sugar rationing had lower rates of several cancers, slower biological ageing, and still ate less sugar at 50. [31]

Why it matters. Rationing ended in September 1953, splitting children born months apart into two groups. That is as close to an experiment as this gets. [31]

Across 2,069 spinal fluid samples, a tau fragment called p-tau205 rose with disease stage and predicted later build-up of amyloid and tau on brain scans. [32]

Why it matters. A marker that moves ahead of the damage gives trials something to measure before symptoms arrive. [32]

Greenland sharks live up to 400 years. UC Irvine researchers found healthy retinal tissue and working blue-light proteins in animals long assumed to be blind. [33]

Why it matters. DNA repair may be what keeps the tissue going. Human eyes have no equivalent. [33]

In mice, a protein called ERBB4 appearing in excitatory neurons drove Alzheimer's damage, with support cells eating those connections while sparing the calming ones. [34]

Why it matters. It suggests the inflammation blamed for early synapse loss may not be needed to cause it. [34]

A Zika vaccine redesigned to avoid a dangerous antibody effect still protected mice - through killer T cells rather than antibodies. That protection was short-lived. [35]

Why it matters. Antibodies were assumed to be the whole defence for this kind of vaccine. Here they were not. [35]

Embryos from older mice were mechanically too stiff: their outer layer squeezed too hard, so the embryo could not spread and settle into the womb. [36]

Why it matters. The same age-linked stiffness showed up in human embryos and IVF records, and can be seen without touching the embryo. [36]

In human brains, faster cognitive decline went with thinner axons, thicker insulation and more myelin-making cells switching off a protein called NRF2. [37]

Why it matters. Aged mice missing NRF2 in those cells showed the same picture, naming a target for keeping thinking sharp. [37]

People fluent in four languages had brains that looked about 13 years younger than single-language speakers, on estimates presented at a European neuroscience meeting. [41]

Why it matters. It is a conference presentation and a correlation. People who learn languages differ in many other ways. [41]

Outer Bio says it keeps donated human skin alive and behaving like skin for about a month, against roughly a week normally, then screens compounds on it. [38]

Why it matters. Its founder Michael Polansky does not want to run it as a drug company. The work is so far a preprint. [38]